17. January 2020 | 13:37 CET
Evotec, Memphasys, MorphoSys - Growth Industry Health
He who is healthy has many desires, he who is ill only one. Companies around the globe deal with diseases and special features of nature in order to treat or cure them. In addition to the widespread disease of cancer, there are also topics that are less talked about, but are also a big market. Developments can be of great importance for investors, physicians and the people affected. It can therefore be worthwhile to deal with the variety of topics.
time to read: 1 minutes by Mario Hose
Expert for drug discovery
Evotec claims to be one of the leading suppliers in the field of active ingredient research, drawing on the know-how accumulated over more than two decades. The company has its headquarters in Hamburg and employs more than 2,900 people worldwide. With a share price of EUR 24.65, Evotec's market capitalization is more than EUR 3.6 billion, making it one of the larger companies in the industry.
Innovations in fertility
Memphasys from Australia is still in the early stages of its corporate development and is working on the topic of artificial insemination to offer couples who wish to have children an improved chance of success for a successful pregnancy. The company's product is called FELIX and is currently in the test phase. A major market launch is scheduled for the second half of 2020. The value of the company on the stock exchange currently amounts to EUR 26 million and a successful operative development should have a corresponding impact.
Experience with antibody technologies
With a share price of EUR 118.70, MorphoSys has a market capitalization of EUR 3.8 billion. According to MorphoSys, it has made a name for itself in the pharmaceutical industry with its antibody technologies. The company develops both its own active ingredients and those of its partners. In drug discovery and development, the Company relies primarily on its innovative technologies. Together with its partners, MorphoSys has built a drug pipeline with more than 100 fully human antibody candidates.